In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa.

MK-0366, a new derivative of nalidixic acid, was tested against 250 urinary pathogens including Escherichia coli, Serratia marcescens, and Pseudomonas aeruginosa. This new agent was more active than any of the other antibiotics tested, which included carbenicillin, ampicillin, cephalexin, tetracycli...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Downs, J, Andriole, V T, Ryan, J L
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 1982
Assuntos:	Research Article
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC181965/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/6211142/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.21.4.670
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!